Author： Meier Florian MP Frerix Marc Müller-Ladner Ulf
Publisher： Future Medicine
ISSN： 1758-4272
Source： International Journal of Clinical Rheumatology, Vol.8, Iss.6, 2013-12, pp. : 689-706
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Raynaud’s phenomenon (RP) can occur as benign, usually primary, RP. By contrast, complex RP is mainly secondary and can be caused by severe, chronic diseases such as systemic sclerosis. This article mainly reviews treatment opportunities for secondary RP, but also refers to primary RP wherever evidence is at hand. The main focus is on drugs recommended by expert panels or research consortia, such as the European League Against Rheumatism Scleroderma Trials and Research (EUSTAR) group. In addition, this review intends to provide a comprehensive overview of the different therapeutic approaches that have been tested in RP to date, some with more impact versus others with less impact. Thereby, conclusions about the pathogenesis of RP can be drawn, which can guide future clinical trials and research.
Related content
Cocaine and Arsenic-Induced Raynaud’s Phenomenon
By Noël B.
Clinical Rheumatology, Vol. 21, Iss. 4, 2002-08 ,pp. :
Access to resources
Recommend
Importance of identification and treatment of Raynaud’’s phenomenon
Future Rheumatology, Vol. 2, Iss. 5, 2007-10 ,pp. :
By Schlager O Kiener HP Stein L Hofkirchner J Zehetmayer S Ristl R Perkmann T Smolen JS Koppensteiner R Gschwandtner ME
Scandinavian Journal of Rheumatology, Vol. 43, Iss. 3, 2014-05 ,pp. :
By Balbir-Gurman Alexandra Braun-Moscovici Yolanda Livshitz Vladimir Schapira Daniel Markovits Doron Rozin Alexander Boikaner Tatiana Nahir A.
Clinical Rheumatology, Vol. 26, Iss. 9, 2007-09 ,pp. :